Verschillende nieuwe analyses naar de optimale duur van de adjuvante behandeling bij coloncarcinoom suggereren dat niet alle patiënten gebaat zijn bij een standaardbehandeling van zes maanden. Vanwege het beperkte klinische voordeel ten opzichte van drie maanden behandeling, heeft bij laagrisicopatiënten een kortere behandeling de voorkeur vanwege de lagere toxiciteit, concludeerde een deskundigenpanel tijdens een speciaal aan dit onderwerp gewijde sessie gedurende het ESMO-congres in Madrid.
Bronnen:
Grothey A, Sobrero A, Meyenhardt JA, et al. Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): Updated results of IDEA (International Duration Evaluation of Adjuvant chemotherapy). ESMO 2017, abstract LBA21_PR.,Iveson T, Kerr R, Saunders M, et al. Updated results of the SCOT study: An International Phase III Randomised (1:1) Non-inferiority Trial Comparing 3 versus 6 months of oxaliplatin based adjuvant chemotherapy for colorectal cancer. ESMO 2107, abstract LBA22.,Labianca R, Lonardi S, Rosati G, et al. FOLFOX4/XELOX in stage II–III colon cancer: efficacy and safety results of the Italian Three Or Six Colon Adjuvant (TOSCA) trial. ESMO 2017, abstract LBA23. ,Yoshino T, Yamanaka T, Kotaka M, et al. Efficacy of 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for Stage III colon cancer (CC): Results from phase III ACHIEVE trial as part of the International Duration Evaluation of Adjuvant therapy (IDEA) Collaboration. ESMO 2017, abstract LBA24.,Taieb J, Bannetain F, Mineur L, et al. Three versus six months adjuvant oxaliplatin-based chemotherapy for patients with stage III colon cancer: per-protocol, subgroups and long-lasting neuropathy results. ESMO 2017, abstract 473O.
Grothey A, Sobrero A, Meyenhardt JA, et al. Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): Updated results of IDEA (International Duration Evaluation of Adjuvant chemotherapy). ESMO 2017, abstract LBA21_PR.,Iveson T, Kerr R, Saunders M, et al. Updated results of the SCOT study: An International Phase III Randomised (1:1) Non-inferiority Trial Comparing 3 versus 6 months of oxaliplatin based adjuvant chemotherapy for colorectal cancer. ESMO 2107, abstract LBA22.,Labianca R, Lonardi S, Rosati G, et al. FOLFOX4/XELOX in stage II–III colon cancer: efficacy and safety results of the Italian Three Or Six Colon Adjuvant (TOSCA) trial. ESMO 2017, abstract LBA23. ,Yoshino T, Yamanaka T, Kotaka M, et al. Efficacy of 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for Stage III colon cancer (CC): Results from phase III ACHIEVE trial as part of the International Duration Evaluation of Adjuvant therapy (IDEA) Collaboration. ESMO 2017, abstract LBA24.,Taieb J, Bannetain F, Mineur L, et al. Three versus six months adjuvant oxaliplatin-based chemotherapy for patients with stage III colon cancer: per-protocol, subgroups and long-lasting neuropathy results. ESMO 2017, abstract 473O.